Naphtho[1,2-b]furan-4,5-dione inactivates EGFR and PI3K/Akt signaling pathways in human lung adenocarcinoma A549 cells

Life Sciences

Volumn 86, Issue 5-6, 2010, Pages 207-213

  Su, Jung Chen ^a   Lin, Kuei Li ^a   Chien, Ching Ming ^a   Tseng, Chih Hua ^a   Chen, Yeh Long ^a   Chang, Long Sen ^b   Lin, Shinne Ren ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

A549; Apoptosis; EGFR; NFD; PI3K Akt

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; CASPASE 3; CASPASE 9; CYCLIN D1; CYTOCHROME C; EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCOGEN SYNTHASE KINASE 3BETA; I KAPPA B ALPHA; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NAPHTHO[1,2 B]FURAN 4,5 DIONE; NAPHTHOQUINONE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; SURVIVIN; TRANSCRIPTION FACTOR FKHR; UNCLASSIFIED DRUG; WORTMANNIN; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME INACTIVATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CASPASE 9; CELL LINE, TUMOR; CELL SURVIVAL; CYTOCHROMES C; CYTOSOL; FLOW CYTOMETRY; HUMANS; LUNG NEOPLASMS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; MOLECULAR STRUCTURE; NAPHTHOQUINONES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 74749094579     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2009.12.006     Document Type: Article

References (40)

1. Adams J.M., Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998, 281(5381):1322-1326.
2. Alt J.R., Cleveland J.L., Hannink M., Diehl J.A. Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes and Development 2000, 14(24):3102-3124.
3. Antonsson B., Martinou J.C. The Bcl-2 protein family. Experimental Cell Research 2000, 256(1):50-57.
4. Arteaga C.L. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Seminars in Oncology 2002, 29(5 Suppl 14):S3-S9.
5. Asanuma H., Torigoe T., Kamiguchi K., Hirohashi Y., Ohmura T., Hirata K., Sato M., Sato N. Survivin expression is regulated by coexpression of human epidermal growth factor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/Akt signaling pathway in breast cancer cells. Cancer Research 2005, 65(23):11018-11025.
6. Bellacosa A., Kumar C.C., Cristofano A.D., Testa J.R. Activation of AKT kinases in cancer: implications for therapeutic targeting. Advances in Cancer Research 2005, 94(15):29-86.
7. Bogdan S., Klambt C. Epidermal growth factor receptor signaling. Current Biology 2001, 11(8):R292-R295.
8. Bowman T., Garcia R., Turkson J., Jove R. STATs in oncogenesis. Oncogene 2000, 19(21):2474-2488.
9. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 2002, 296(5573):1655-1657.
10. Chen Y.L., Chen I.L., Wang T.C., Han C.H., Tzeng C.C. Synthesis and anticancer evaluation of certain 4-anilinofuro[2,3-b]quinoline and 4-anilinofuro[3,2-c]quinoline derivatives. European Journal of Medicinal Chemistry 2005, 40(9):928-934.
11. Citri A., Yarden Y. EGF-ERBB signaling: towards the systems level. Nature Reviews Molecular Cell Biology 2006, 7(7):505-516.
12. Cross D.A., Alessi D.R., Cohen P., Andjelkovich M., Hemmings B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995, 378(6559):785-789.
13. Datta S.R., Brunet A., Greenberg M.E. Cellular survival: a play in three Akts. Genes and Development 1999, 13(22):2905-2927.
14. Gardai S.J., Hildeman D.A., Frankel S.K., Whitlock B.B., Frasch S.C., Borregaard N., Marrack P., Bratton D.L., Henson P.M. Phosphorylation of Bax Ser184 by Akt regulates its activity and apoptosis in neutrophils. Journal of Biological Chemistry 2004, 279(20):21085-21095.
15. Goulart M.O.F., Zani C.L., Tonholo J., Freitas L.R., Abreu F.C., Oliveira A.B., Raslan D.S., Starling S., Chiari E. Trypanocidal activity and redox potential of heterocyclic- and 2-hydroxy-naphthoquinines. Bioorganic and Medicinal Chemistry Letters 1997, 7(15):2043-2048.
16. Gross A., McDonnell J.M., Korsmeyer S.J. Bcl-2 family members and the mitochondria in apoptosis. Genes and Development 1999, 13(15):1899-1991.
17. Havasi A., Li Z.J., Wang Z.Y., Martin J.L., Botla V., Ruchalski K., Schwartz J.H., Borkan S.C. Hsp27 inhibits Bax activation and apoptosis via a phosphatidylinositol 3-kinase-dependent mechanism. Journal of Biological Chemistry 2008, 283(18):12305-12313.
18. Huang S.H., Chen Y., Tung P.Y., Wu J.C., Chen K.H., JM W.U., Wang S.M. Mechanisms for the magnolol-induced cell death of CGTH W-2 thyroid carcinoma cells. Journal of Biological Chemistry 2007, 101(4):1011-1022.
19. Ito C., Katsuno S., Kondo Y., Tan H.T.W., Furukawa H. Chemical constituents of Avicennia alba. Isolation and structural elucidation of new naphoquinones and their analogues. Chemical and Pharmaceutical Bulletin 2000, 48(3):339-343.
20. Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M.J. Cancer statistics, 2007. CA: A Cancer Journal for Clinicians 2007, 57(1):43-66.
21. Karin M., Yinon B.N. Phosphorylation meets ubiquitination: the control of NFκB activity. Annual Review of Immunology 2000, 18(1):621-663.
22. Kelly K. The role of targeted agents in adjuvant therapy for non-small cell lung cancer. Clinical Cancer Research 2005, 11(13 Pt 2):5027s-5029s.
23. Kongkathip N., Kongkathip B., Siripong P., Sanqma C., Luangkamin S., Niyomdecha M., Pattanapa S., Piyaviriyagul S., Kongsaeree P. Potent antitumor activity of synthetic 1, 2-naphoquinones and 1, 4-naphoquinones. Bioorganic and Medicinal Chemistry 2003, 11(14):3179-3191.
24. Kumar R., Srinivasan S., Koduru S., Pahari P., Rohr J., Kyprianou N., Damodaran C. Psoralidin, an herbal molecule inhibits phosphatidylinositol 3-kinase-mediated Akt signaling in androgen-independent prostate cancer cells. Cancer Prevention Research 2009, 2(3):234-243.
25. Lee Y.R., Kim B.S., Jung Y.U., Koh W.S., Cha J.S., Kim N.W. Facile synthesis of avicequinone-B natural product. Synthetic Communications 2002, 32(20):3099-3105.
26. Levitzki A., Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science 1995, 267(5205):1782-1788.
27. Liu W., Akhand A.A., Kato M., Yokoyama I., Miyata T., Kurokawa K., Uchida K., Nakashima I. 4-Hydroxynonenal triggers an epidermal growth factor receptor-linked signal pathway for growth inhibition. Journal of Cell Science 1999, 112(Pt 14):2409-2417.
28. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. Journal of Clinical Oncology 2002, 20(18 Suppl):S1-S13.
29. Nakanishi K., Sakamoto M., Yamasaki S., Todo S., Hirohashi S. Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer 2005, 103(2):307-312.
30. Ozes O.N., Mayo L.D., Gustin J.A., Pfeffer S.R., Pfeffer L.M., Donner D.B. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999, 401(6748):82-85.
31. Pugazhenthi S., Nesterova A., Sable C., Heidenreich K.A., Boxer L.M., Heasley L.E., Reusch J.E. Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-responsive element-binding protein. Journal of Biological Chemistry 2000, 275(15):10761-10766.
32. Raez L.E., Lilenbaum R. Chemotherapy for advanced non-small-cell lung cancer. Clinical Advances in Hematology and Oncology 2004, 2(3):173-178.
33. Salvesen G.S., Dixit V.M. Caspases: intracellular signaling by proteolysis. Cell 1997, 91(4):443-446.
34. Shen J., Jiang J., Wei Y., Zhou L., Liu D., Zhou J., Gu J. Two specific inhibitors of the phosphatidylinositol 3-kinase LY294002 and wortmannin up-regulate β1, 4-galactosyltransferase 1 and thus sensitize SMMC-7721 human hepatocarcinoma cells to cycloheximide-induced apoptosis. Molecular and Cellular Biochemistry 2007, 304(1-2):361-367.
35. Shin D.M., Ro J.Y., Hong W.K., Hittelman W.N. Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Research 1994, 54(12):3153-3159.
36. Steinke K. Lung tumors. Recent Results in Cancer Research 2006, 167(5):107-122.
37. Sutton D.C., Gillan F.T., Susic M. Naphthofuranone phytoalexins from the gray mangrove, Avicennia marina. Phytochemistry 1985, 24(6):2877-2879.
38. Tseng C.H., Lin C.S., Shi P.K., Tsao L.T., Wang J.P., Cheng C.M., Tzeng C.C., Chen Y.L. Furo[3', 2':3, 4]naphtha[1, 2-d]imidaxole derivatives as potential inhibitors of inflammatory factors in sepsis. Bioorganic and Medicinal Chemistry 2009, 17(18):6773-6779.
39. Yarden Y., Sliwkowski M.X. Untangling the ErbB signaling network. Nature Reviews Molecular Cell Biology 2001, 2(2):127-137.
40. Youle R.J., Strasser A. The Bcl-2 protein family: opposing activities that mediate cell death. Nature Reviews Molecular Cell Biology 2008, 9(1):47-59.